JP2010505958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505958A5 JP2010505958A5 JP2009532414A JP2009532414A JP2010505958A5 JP 2010505958 A5 JP2010505958 A5 JP 2010505958A5 JP 2009532414 A JP2009532414 A JP 2009532414A JP 2009532414 A JP2009532414 A JP 2009532414A JP 2010505958 A5 JP2010505958 A5 JP 2010505958A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- absent
- composition according
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 208000012902 Nervous system disease Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- -1 X 22 Chemical compound 0.000 claims 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000010496 Heart Arrest Diseases 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 1
- 208000020564 Eye injury Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000003225 hyperhomocysteinemia Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000011475 meningoencephalitis Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 231100000878 neurological injury Toxicity 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 208000005877 painful neuropathy Diseases 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 208000032253 retinal ischemia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 0 *C(*)c1cc(C(*)C(*[I+])C2C3(*)CCCC2(*)*)c3c(O)c1O Chemical compound *C(*)c1cc(C(*)C(*[I+])C2C3(*)CCCC2(*)*)c3c(O)c1O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85091806P | 2006-10-10 | 2006-10-10 | |
| US85086006P | 2006-10-10 | 2006-10-10 | |
| PCT/US2007/021748 WO2008108825A2 (en) | 2006-10-10 | 2007-10-10 | Neuroprotective compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010505958A JP2010505958A (ja) | 2010-02-25 |
| JP2010505958A5 true JP2010505958A5 (OSRAM) | 2010-11-25 |
Family
ID=39738942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009532414A Pending JP2010505958A (ja) | 2006-10-10 | 2007-10-10 | 神経防護作用組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8022246B2 (OSRAM) |
| EP (1) | EP2086318A4 (OSRAM) |
| JP (1) | JP2010505958A (OSRAM) |
| CA (1) | CA2666461A1 (OSRAM) |
| WO (1) | WO2008108825A2 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101580857B1 (ko) | 2007-02-06 | 2015-12-30 | 네우로퀘스트 아이엔씨. | 신경 전달을 억제하기 위한 테르펜 화합물을 포함하는 조성물 및 방법 |
| EP2326323A4 (en) | 2008-08-13 | 2012-02-22 | Neuroquest Inc | COMPOSITION COMPRISING TERPENE COMPOUNDS FOR THE TREATMENT OF NEGATIVE SENSORY PHENOMENA |
| JP2012502064A (ja) | 2008-09-10 | 2012-01-26 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化還元活性治療剤を用いての広汎性発達障害の処置 |
| GB2464813A (en) * | 2009-10-23 | 2010-05-05 | Univ Sheffield | Treatments for neurodegenerative disorders |
| WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| RU2765155C2 (ru) | 2010-09-10 | 2022-01-26 | Эпизайм, Инк. | Ингибиторы ezh2 человека и способы их применения |
| EP2616056A4 (en) * | 2010-09-14 | 2014-03-12 | Neuroquest Inc | TERPENOID ANALOGUES AND USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| WO2012094580A2 (en) * | 2011-01-07 | 2012-07-12 | High Point Pharmaceuticals, Llc | Compounds that modulate oxidative stress |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| WO2013067036A1 (en) * | 2011-10-31 | 2013-05-10 | Rutgers, The State University Of New Jersey | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| EP2830611B1 (en) * | 2012-03-30 | 2016-04-27 | Nestec S.A. | 4-oxo-2-pentenoic acid and brain health |
| SG10201608577RA (en) | 2012-04-13 | 2016-12-29 | Epizyme Inc | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
| NZ706738A (en) | 2012-10-15 | 2018-10-26 | Epizyme Inc | Substituted benzene compounds |
| US20150320795A1 (en) | 2012-12-13 | 2015-11-12 | Roy JOSEE | Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury |
| CN105431405B (zh) * | 2013-03-14 | 2018-06-01 | 澳门大学 | 分离自益智仁的新抗神经变性天然化合物及其全合成 |
| LT3057962T (lt) | 2013-10-16 | 2023-12-11 | Epizyme, Inc. | Hidrochlorido druskos forma, skirta ezh2 inhibavimui |
| CN112047910B (zh) * | 2015-04-30 | 2023-02-21 | 杭州百诚医药科技股份有限公司 | 芳香族法尼基类化合物及其应用 |
| US10123991B2 (en) | 2015-05-15 | 2018-11-13 | Global Biolife Inc. | Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders |
| PT3106160T (pt) | 2015-06-15 | 2020-01-30 | Neuralia | Composição de combinação compreendendo huperzina |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| PT3833662T (pt) | 2018-08-20 | 2024-03-18 | Janssen Pharmaceutica Nv | Inibidores da interação proteína-proteína keap1-nrf2 |
| CN111166885B (zh) * | 2020-01-16 | 2022-03-15 | 上海交通大学医学院 | 神经保护剂及其用途 |
| CN114588143B (zh) * | 2020-12-03 | 2023-06-06 | 中国科学院大连化学物理研究所 | 药物组合物及化合物作为或在制备阿片受体拮抗剂中的应用 |
| US20250122146A1 (en) * | 2021-09-30 | 2025-04-17 | The Scripps Research Institute | Compounds for reducing neuroinflammation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3976782A (en) * | 1975-03-25 | 1976-08-24 | Merck & Co., Inc. | 3-(2,5-Dihydroxyphenyl)-alanine as a cardiac stimulant |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| ES2069281T3 (es) | 1990-03-06 | 1995-05-01 | Otsuka Pharma Co Ltd | Derivado de fenantreno. |
| DE69012566T2 (de) | 1990-10-06 | 1995-02-02 | Nestle Sa | Verfahren zur Gewinnung von Carnosäure. |
| CA2220223C (en) | 1995-05-05 | 2008-07-29 | Hauser Inc. | High purity carnosic acid from rosemary and sage extracts by ph-controlled precipitation |
| BR9714605A (pt) | 1997-04-16 | 2002-05-21 | Lycored Natural Prod Ind Ltd | Processo para produzir um extrato antioxidante natural e ácido carnósico |
| JP2001233835A (ja) * | 2000-02-28 | 2001-08-28 | Nagase & Co Ltd | カルノジン酸誘導体およびそれを用いた神経成長因子合成促進剤 |
| WO2002002190A2 (en) * | 2000-07-05 | 2002-01-10 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| US20040014808A1 (en) | 2002-04-09 | 2004-01-22 | Rosazza John P.N. | Novel derivatives of carnosic acid |
| GB0216371D0 (en) * | 2002-07-13 | 2002-08-21 | Rowett Res Inst The | Compounds |
| US7129374B2 (en) * | 2002-11-26 | 2006-10-31 | Florida Atlantic University | Catalytic antioxidants and methods of use |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| PL1803468T3 (pl) * | 2003-12-22 | 2012-05-31 | Novartis Ag | Środki do leczenia retinopatii jaskrowej i neuropatii wzrokowej |
| MX2008004981A (es) * | 2005-10-16 | 2008-10-17 | Lycored Ltd | Composiciones para el tratamiento de enfermedades de los ojos. |
-
2007
- 2007-10-10 WO PCT/US2007/021748 patent/WO2008108825A2/en not_active Ceased
- 2007-10-10 JP JP2009532414A patent/JP2010505958A/ja active Pending
- 2007-10-10 EP EP07873874A patent/EP2086318A4/en not_active Withdrawn
- 2007-10-10 US US11/974,114 patent/US8022246B2/en not_active Expired - Fee Related
- 2007-10-10 CA CA002666461A patent/CA2666461A1/en not_active Abandoned
-
2011
- 2011-09-19 US US13/236,579 patent/US8466311B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505958A5 (OSRAM) | ||
| JP2007523168A5 (OSRAM) | ||
| JP2013523846A5 (OSRAM) | ||
| JP2013526544A5 (OSRAM) | ||
| JP2018518537A5 (OSRAM) | ||
| EP4306524A3 (en) | Lymphatic system-directing lipid prodrugs | |
| JP2013545730A5 (OSRAM) | ||
| JP2014511892A5 (OSRAM) | ||
| RU2014151622A (ru) | Композиции и способы лечения нейродегенеративных заболеваний | |
| JP2007500757A5 (OSRAM) | ||
| JP2009504748A5 (OSRAM) | ||
| BR112014009927A2 (pt) | "derivado de azol, composição farmacêutica que o compreende e uso do mesmo" | |
| SG11201407973SA (en) | Prodrug of fluorine-containing amino acid | |
| WO2009017236A1 (ja) | ピリドピリミジン－４－オン誘導体 | |
| JP2014526508A5 (OSRAM) | ||
| WO2014129495A1 (ja) | 眼疾患処置薬 | |
| JP2004536111A5 (OSRAM) | ||
| WO2015129809A1 (ja) | 虚血性眼疾患の処置用の医薬組成物 | |
| JP2022518003A (ja) | ケタミンパモエート及びその使用 | |
| JP2013544245A5 (ja) | ネプリライシンの発現および活性を増大させるための医薬組成物 | |
| RU2013153140A (ru) | Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат | |
| JP2005524696A5 (OSRAM) | ||
| JP2016537432A5 (OSRAM) | ||
| JP2007530703A5 (OSRAM) | ||
| HRP20140326T1 (hr) | Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat |